# Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

> **NCT00427856** · PHASE2 · COMPLETED · sponsor: **Gemin X** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Obatoclax mesylate
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00427856
- **Lead sponsor:** Gemin X
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427856, "Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00427856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*